following a full submission:
ustekinumab (Stelara®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies.
Ustekinumab was associated with improved clinical response and remission versus placebo during induction and maintenance treatment in patients with moderately to severely active Crohn’s disease who had failed to respond to or not tolerated conventional therapy or TNFα antagonists.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ustekinumab. The advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice340KB (PDF)
Medicine details
- Medicine name:
- ustekinumab (Stelara)
- SMC ID:
- 1250/17
- Indication:
- For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha antagonist or have medical contraindications to such therapies.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 July 2017